- Investing Ideas
- /
- U.S. Biotech Breakthroughs
U.S. Biotech Breakthroughs
Results
53
Biotech stocks worldwide which are expected to become profitable in the next 3 years.
53 companies
Madrigal Pharmaceuticals
Market Cap: US$11.1b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$489.31
7D
1.8%
1Y
46.1%
Arcutis Biotherapeutics
Market Cap: US$3.1b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$25.37
7D
-3.2%
1Y
91.6%
Ardelyx
Market Cap: US$1.9b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$7.69
7D
-1.0%
1Y
43.5%
Marker Therapeutics
Market Cap: US$26.7m
A clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.
MRKR
US$1.60
7D
-23.8%
1Y
-13.0%
Lineage Cell Therapeutics
Market Cap: US$358.6m
A clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally.
LCTX
US$1.48
7D
-8.1%
1Y
146.4%
RenovoRx
Market Cap: US$38.1m
A clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment.
RNXT
US$1.04
7D
4.4%
1Y
-23.5%
Pelthos Therapeutics
Market Cap: US$74.1m
A bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
PTHS
US$24.02
7D
-2.9%
1Y
2.6%
Achieve Life Sciences
Market Cap: US$222.5m
A late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom.
ACHV
US$4.18
7D
-25.4%
1Y
27.8%
Capricor Therapeutics
Market Cap: US$1.1b
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$21.89
7D
-5.6%
1Y
45.5%
Soleno Therapeutics
Market Cap: US$2.1b
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.
SLNO
US$38.56
7D
-9.0%
1Y
-23.2%
Aldeyra Therapeutics
Market Cap: US$322.5m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases.
ALDX
US$5.36
7D
3.3%
1Y
2.3%
ARS Pharmaceuticals
Market Cap: US$987.5m
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions.
SPRY
US$9.99
7D
-2.2%
1Y
-23.3%
Longeveron
Market Cap: US$11.9m
A clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States.
LGVN
US$0.56
7D
-4.3%
1Y
-63.7%
Syndax Pharmaceuticals
Market Cap: US$1.8b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$20.31
7D
0.3%
1Y
43.3%
Citius Oncology
Market Cap: US$93.6m
Focuses on the development and commercialization of innovative targeted oncology therapies.
CTOR
US$1.06
7D
-6.2%
1Y
-11.7%
Viridian Therapeutics
Market Cap: US$3.1b
Engages in discovering, developing, and commercializing treatments for serious and rare diseases.
VRDN
US$33.00
7D
0.2%
1Y
70.3%
Caris Life Sciences
Market Cap: US$6.5b
An artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally.
CAI
US$23.16
7D
-7.4%
1Y
n/a
Precigen
Market Cap: US$1.6b
A discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.
PGEN
US$4.49
7D
-5.7%
1Y
232.6%
AC Immune
Market Cap: US$315.6m
A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
ACIU
US$3.19
7D
-13.8%
1Y
16.0%
Altimmune
Market Cap: US$611.3m
A clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases.
ALT
US$5.60
7D
1.8%
1Y
-15.7%
Vera Therapeutics
Market Cap: US$3.1b
A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases.
VERA
US$43.26
7D
-8.9%
1Y
16.0%
Insmed
Market Cap: US$33.5b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$156.87
7D
0.4%
1Y
104.8%
Ocugen
Market Cap: US$475.4m
A biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health.
OCGN
US$1.45
7D
-12.7%
1Y
99.3%
Unicycive Therapeutics
Market Cap: US$128.3m
A clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States.
UNCY
US$5.97
7D
-13.7%
1Y
-2.7%
Rhythm Pharmaceuticals
Market Cap: US$6.8b
A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases.
RYTM
US$102.52
7D
-0.3%
1Y
72.5%
Roivant Sciences
Market Cap: US$15.0b
A clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies.
ROIV
US$21.62
7D
-4.3%
1Y
94.2%
Praxis Precision Medicines
Market Cap: US$8.7b
A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance.
PRAX
US$314.00
7D
0.7%
1Y
310.2%
BioRestorative Therapies
Market Cap: US$10.1m
Develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells.
BRTX
US$1.14
7D
0%
1Y
-52.1%
Amicus Therapeutics
Market Cap: US$4.4b
A biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally.
FOLD
US$14.29
7D
0.1%
1Y
49.2%
Cogent Biosciences
Market Cap: US$5.5b
A biotechnology company, focuses on developing precision therapies for genetically defined diseases.
COGT
US$35.91
7D
-2.1%
1Y
285.7%
Ionis Pharmaceuticals
Market Cap: US$13.4b
A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
IONS
US$82.67
7D
3.0%
1Y
159.2%
Fortress Biotech
Market Cap: US$96.2m
A biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products.
FBIO
US$3.10
7D
-8.8%
1Y
70.3%
Zymeworks
Market Cap: US$1.7b
A clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID).
ZYME
US$22.53
7D
-3.1%
1Y
54.3%
Creative Medical Technology Holdings
Market Cap: US$7.1m
A commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States.
CELZ
US$2.02
7D
-3.8%
1Y
-35.5%
Prelude Therapeutics
Market Cap: US$152.4m
A clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.
PRLD
US$1.85
7D
-8.4%
1Y
68.2%
Savara
Market Cap: US$1.3b
A clinical stage biopharmaceutical company, focuses on rare respiratory diseases.
SVRA
US$5.40
7D
-10.3%
1Y
100.0%